Adverse events associated with budesonide nasal irrigation reported to the US Food and Drug Administration: 2007 to 2022.
Adverse events associated with budesonide nasal irrigation reported to the US Food and Drug Administration: 2007 to 2022.
复制标题
向美国食品和药物管理局报告的与布地奈德鼻腔冲洗相关的不良事件：2007 年至 2022 年。
DOI：
10.1002/alr.23232
复制
发表时间：
2024
影响因子：
6.4
通讯作者：
Gray,StaceyT
中科院分区：
文献类型：
--
作者：
Rathi,VinayK;Sawicki,NicholasW;Schlosser,RodneyJ;Soler,ZacharyM;Scangas,GeorgeA;Workman,AlanD;Gray,StaceyT
摘要要点：在2007年至2022年期间，FDA收到了119份涉及布地奈德鼻腔冲洗的美国报告。大多数报告由患者提交，并提醒FDA注意布地奈德的标签外用药。向FDA报告的显著不良事件包括头痛、呼吸困难和视力模糊。
Abstract KEYPOINTS: Between 2007 and 2022, the FDA received 119 US‐based reports mentioning budesonide nasal irrigation. Most reports were submitted by patients and alerted FDA to off‐label usage of budesonide. Notable adverse events reported to the FDA included headache, dyspnea, and blurred vision.